The new Pixel by Labcorp Covid-19+Flu+RSV test home collection kit can be used by children and adults aged two years and above, without requiring a prescription
The new Covid-19+Flu+RSV test home collection kit requires no prescription. (Credit: Laboratory Corporation of America)
Labcorp has received the US Food and Drug Administration (FDA) emergency use authorisation (EUA) for an at-home collection kit that simultaneously detects Covid-19, influenza A/B and respiratory syncytial virus (RSV).
The new Pixel by Labcorp Covid-19+Flu+RSV test home collection kit is indicated for use by individuals aged two years and above, without requiring a prescription.
Shipped through FedEx Priority Overnight to the individuals’ homes, the kit can be used through the Labcorp OnDemand digital health platform.
The samples collected using the Pixel by Labcorp Covid-19+Flu+RSV test home collection kit are returned to Labcorp through a prepaid return envelope.
Individuals will receive the test results on their Labcorp OnDemand account, within one or two days after Labcorp receives the completed collection kit.
The diagnostic testing company is offering the home collection kit at no upfront cost for people who meet clinical guidelines and are covered by insurance.
Labcorp Diagnostics chief medical officer and president Brian Caveney said: “Labcorp’s Covid-19 tests have been trusted by physicians and millions of people throughout the pandemic.
“This new at-home collection kit makes it easier for consumers to access testing for multiple respiratory viruses, Covid-19, the flu and RSV – that can present similar symptoms.
“With the spike in RSV cases over the last year, the continued presence of COVID-19, and the ever-present threat of flu, testing for all three viruses at once enables individuals and physicians to quickly identify the illness and determine the appropriate treatment.”
In a separate development, Labcorp has rolled out a new test for people with skin cancer, which is available for use in both clinical trials and for the care and treatment of patients.
The new test is designed to measure the expression levels of Lymphocyte-activation gene 3 (LAG-3) by immunohistochemistry (IHC) in tumour tissue.
As LAG-3 is an immune-oncology target with clinical benefits in patients with melanoma, the test is said to simplify the selection of treatment options for patients with skin cancer.
Labcorp senior vice president and oncology head Prasanth Reddy said: “Our goal is to provide diagnostic solutions that can help guide the clinical application of new cancer treatments, improving the lives of those living with cancer.
“The LAG-3 IHC assay provides physicians with actionable information to evaluate the best treatment options, including newly approved treatments and clinical trials, for their patients.”
Recently, Labcorp launched an at-home collection kit to measure diabetes risk by detecting the level of haemoglobin A1c (HbA1c) from a small blood sample.